Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.48 |
| ▸ | HTR2C | P28335 | 13/20 | 0.48 |
| ▸ | HTR2B | P41595 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365641 | 0.73 | HTR2A (0.43) | HTR2AHTR2CHTR2BDRD1DRD5 | |
| SCHEMBL21661793 | 0.69 | HTR2A (0.59) | HTR2AHTR2CHTR2B | |
| SCHEMBL1105042 | 0.67 | HTR2C (0.72) | HTR2AHTR2CHTR2BDRD1DRD5 | |
| SCHEMBL1095157 | 0.67 | HTR2C (0.72) | HTR2AHTR2CHTR2BDRD1DRD5 | |
| SCHEMBL1095159 | 0.67 | HTR2C (0.72) | HTR2AHTR2CHTR2BDRD1DRD5 | |
| SCHEMBL22609757 | 0.66 | HTR2C (0.60) | HTR2AHTR2CHTR2BALDH1A1DRD1 | |
| SCHEMBL1095292 | 0.65 | HTR2C (1.00) | HTR2AHTR2CHTR2B | |
| SCHEMBL1097026 | 0.65 | HTR2C (1.00) | HTR2AHTR2CHTR2B | |
| SCHEMBL1097029 | 0.65 | HTR2C (1.00) | HTR2AHTR2CHTR2B | |
| SCHEMBL3162737 | 0.64 | HTR2A (0.74) | HTR2AHTR2CHTR2BMAOATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363394-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |